515 POSTER Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis

2007 ◽  
Vol 5 (4) ◽  
pp. 94
Author(s):  
P. Major ◽  
V. Hirsh ◽  
A. Lipton ◽  
R.J. Cook ◽  
R.E. Coleman
2019 ◽  
Vol 57 (1) ◽  
pp. 114-121 ◽  
Author(s):  
Yoshinori Handa ◽  
Yasuhiro Tsutani ◽  
Takahiro Mimae ◽  
Yoshihiro Miyata ◽  
Morihito Okada

AbstractOBJECTIVESAlthough segmentectomy for lung cancer has been widely accepted, complex segmentectomy, which creates several, intricate intersegmental planes, remains controversial. Potential arguments include risk of incurability and ‘failure of cancer control’. We compared the outcomes of complex segmentectomy versus lobectomy and evaluated its use in lung cancer treatment.METHODSWe retrospectively reviewed clinical stage IA lung cancer patients who underwent complex segmentectomy (n = 99) or location-adjusted lobectomy (n = 94) between April 2009 and December 2017. Clinicopathological and postoperative results were compared. Factors affecting survival were assessed by the Kaplan–Meier method and the Cox regression analysis.RESULTSNo significant differences were detected in 30-day mortality (0% vs 0%), overall complications (26.3% vs 21.3%) and prolonged air leakage (11.1% vs 9.6%) rates between the 2 groups, respectively. Comparable results were obtained for 5-year overall (93.5% vs 96.4%, respectively; P = 0.21) or recurrence-free (92.3% vs 88.5%, respectively; P = 0.82) survivals after complex segmentectomy or lobectomy. There were 2 (2.0%) recurrences after complex segmentectomy and 7 (7.5%) after lobectomy (P = 0.094), with 0 (0%) margin relapses in each group. Multivariable Cox regression analysis revealed that complex segmentectomy and lobectomy had a numerically similar impact on recurrence-free survival (hazard ratio 0.93, 95% confidence interval 0.32–2.69; P = 0.90).CONCLUSIONSComplex segmentectomy can provide acceptable short- and long-term outcomes in lung cancer treatment.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18211-18211
Author(s):  
S. R. Bella ◽  
M. E. Richardet ◽  
P. Gomez Storniolo ◽  
P. Celiz ◽  
A. Lingua ◽  
...  

18211 Background: Prognostic factors identified in advanced non small cell lung cancer are: age, gender, PS, h. SWOG univariable analysis in patients with chemotheraphy; confirmed these factors and show a relationship between the hemoglobin level and the overall survival; in addition the metastasic site number and cisplatin- based chemotheraphy (7). To analyse and compare the hemoglobin level before cisplatin- based chemotheraphy with survival in patients with advanced non- small cell lung cancer. Methods: Retrospective study conducted at the IONC of the 179 clinical record were analized, over a 5 year period. The collected data were: age, gender, PS, histologic type, stage, chemotheraphy cycles number, smooke history, number and metastasic site. We analyzed median and overal survival using Kaplan Meier, and the anemia as a prognostic implication factor with univariable and multivariable Cox regression analysis. Istologic type and TNM (1–6). Results: The mean age was 59 (40–79); 146 (81.5%) male and 33 (18.5%) women; histological types found were squamous cell carcinomas in 66 (37%), and adenocarcinoma in 113 (63%); stage IIIB in 61 (34%) and IV in 118 (66%). 147 (82%) were smokers and 32 (18%) were never smokers. All the patients had PS 0–1. Median overall survival time was 11.53 months and 13.88 months in the haemoglobin level < or > 11 gr/ 100 ml, respectively. (p=0.3). In univariable Cox regression analysis, smoking rates and chemotheraphy cycles number were predictors of survival (p=0.05 y p=0.018, respectively). Hemoglobine (p=0.55). In multivariable Cox regression analysis, only the number of cycles was predictor of survival (p=0.026). Hemoglobine (p=0.34). Conclusions: In our experience, a greater survival tendency was observed in patients with advanced non- small cell lung cancer who presented levels of Hemoglobine greater than 11 gr/dl, previous to cisplatin- based chemotherapy without statistical significance. [Table: see text]


2021 ◽  
Author(s):  
jun wang ◽  
huawei li ◽  
ran xu ◽  
tong lu ◽  
jiaying zhao ◽  
...  

Abstract ObjectiveThe purpose of this paper is to predict the following items. preoperative baseline monocyte-to-lymphocyte ratio (MLR)、neutrophil-to-lymphocyte ratio (NLR) Platura-to-lymphocyte ratio (PLR) and dimeric fibrin fragment D (D-dimer) associated with clinical outcome in patients with Early Lung Cancer (LC).MethodsWe performed a retrospective analysis of 376 patients with LC. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier, and univariate and multivariate Cox regression analyses were performed to identify prognostic factors. Finally, multivariate Cox regression analysis was used to evaluate the influence of favorable factors on patients’ OS and PFS combined with the basic clinical characteristics of the patient ResultsAmong the variables screened by univariate Cox regression, MLR < 0.22, NLR < 1.99, PLR < 130.55 and D-Dimer < 70.5 (ng/ml) were significantly associated with both better OS and PFS. In multivariate Cox regression analysis, it was determined that MLR and D-Dimer had a better independent correlation with OS (p = 0.009, p = 0.05, respectively), while MLR was only better independently associated with PFS (P = 0.005). Furthermore, according to the number of favorable factors, patients with none of these factors had a significantly worse prognosis than patients with at least one of these factors.ConclusionBaseline characteristics of low MLR, low NLR, low PLR and low D-dimer were associated with better outcomes.


2020 ◽  
Author(s):  
Rong Wei ◽  
Ziyue Wang ◽  
Yaping Zhang ◽  
Bin Wang ◽  
Ningning Shen ◽  
...  

Abstract Background Lung cancer has been the leading cause of tumor related death, and 80%~85% of it is non-small cell lung cancer (NSCLC). Even with the rising molecular targeted therapies, for example EGFR, ROS1 and ALK, the treatment is still challenging. The study is to identify credible responsible genes during the development of NSCLC using bioinformatic analysis, developing new prognostic biomarkers and potential gene targets to the disease. Methods Firstly, three genes expression profiles GSE44077, GSE18842 and GSE33532 were picked from Gene Expression Omnibus (GEO) to analyze the genes with different expression level (GDEs) between NSCLC and normal lung samples, and the cellular location, molecular function and the biology pathways the GDEs enriched in were analyzed. Then, gene function modules of GDEs were explored based on the protein-protein interaction network (PPI), and the top module which contains most genes was identified, followed by containing genes annotation and survival analysis. Moreover, multivariate cox regression analysis was performed in addition to the Kaplan meier survival to narrow down the key genes scale. Further, the clinical pathological features of the picked key genes were explored using TCGA data. Results Three GEO profiles shared a total of 664 GDEs, including 232 up-regulated and 432 down-regulated genes. Based on the GDEs PPI network, the top function module containing a total of 69 genes was identified, and 31 of 69 genes were mitotic cell cycle regulation related. And survival analysis of the 31 genes revealed that 17/31 genes statistical significantly related to NSCLC overall survival, including 4 spindle assembly checkpoints, namely NDC80, BUB1B, MAD2L1 and AURKA. Further, multivariate cox regression analysis identified NDC80 and MAD2L1 as independent prognostic indicators in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) respectively. Interestingly, pearson correlation analysis indicated strong connection between the four genes NDC80, BUB1B, MAD2L1 and AURKA, and their clinical pathological features were addressed. Conclusions Using bioinformatic analysis of GEO combined with TCGA data, we revealed two independent prognostic indicators in LUAD and LUSC respectively and analyzed their clinical features. However, more detailed experiments and clinical trials are needed to verify their drug targets role in clinical medical use.


2021 ◽  
Author(s):  
Xiaoyan Chen ◽  
Lisha Hou ◽  
Jianqun Li ◽  
Yanjiao Shen ◽  
Fucha Tan ◽  
...  

Abstract Objective: To evaluate the accuracy of baselineserum uric acid(BSUA) in estimating adverse effects (AE) and all-cause mortality (ACM) in older males with stage IIIB or IV non-small cell lung cancer (NSCLC) diagnosis.Study design:This is a single-center retrospective examination, conducted at the West China Hospital, Sichuan University in Chengdu, Sichuan Province, China, between the duration of January 2010 and December 2017.Primary outcome and measures:: All patients data was obtained based on medical reports and mortality information was gathered via telephone interviews. BUSA was assessed prior to chemotherapy. Additionally, the end points of this study included chemotherapy-mediated AE and ACM. Binarylogistic regression analysis was used to explore the correlation between BSUA and AE. Lastly, Cox regression analysis was utilized to examine theimpactof BSUA on ACM.Results: 317 male patients with NSCLC were eligible for this study. Within this population, 18.3% had stage IIIB and 81.7% had stage IV NSCLC. Moreover, 81.39% suffered from adenocarcinoma lung cancer (ACLC), whereas 18.61% suffered from squamous cell carcinoma lung cancer (SCCLC). As of March 1, 2019, 257 (81.07%) patients expired. Following the initial chemotherapeutic course, short-term AE like bone marrow suppression, all infection, liver dysfunction, and digestive reactions, wereobserved in 13.25%, 7.26%, 5.36%, and 4.1% of cases, respectively. Upon normalizing with confounding factors, the adjustedlogistic regression model demonstrated thatthe moderate BSUA was independently linked to a lower risk of bone marrow suppression (OR=0.407,95% CI:0.178-0.931; p=0.033).Moreover, based on the Cox regression analysis, moderate BSUAwas also independently correlated with a low mortality risk (HR=0.705,95% CI:0.518-0.959; p=0.026).Conclusion:In males patients withstage IIIB or IV NSCLC, BSUA is intimately linked to chemotherapy-driven AE and ACM.


2021 ◽  
Author(s):  
Xiaoyan Chen ◽  
Lisha Hou ◽  
Jianqun Li ◽  
Yanjiao Shen ◽  
Birong Dong ◽  
...  

Abstract Objective: To evaluate the accuracy of baseline serum uric acid (BSUA) in estimating adverse effects (AE) and all-cause mortality (ACM) in older males with stage IIIB or IV non-small cell lung cancer (NSCLC) diagnosis.Methods: All patients data was obtained based on medical reports and mortality information was gathered via telephone interviews. BUSA was assessed prior to chemotherapy. Additionally, the end points of this study included chemotherapy-mediated AE and ACM. Binary logistic regression analysis was used to explore the correlation between BSUA and AE. Lastly, Cox regression analysis was utilized to examine the impact of BSUA on ACM.Results: 317 male patients with NSCLC were eligible for this study. Within this population, 18.3% had stage IIIB and 81.7% had stage IV NSCLC. Moreover, 81.39% suffered from adenocarcinoma lung cancer (ACLC), whereas 18.61% suffered from squamous cell carcinoma lung cancer (SCCLC). As of March 1, 2019, 257 (81.07%) patients expired. Following the initial chemotherapeutic course, short-term AE like bone marrow suppression, all infection, liver dysfunction, and digestive reactions, were observed in 13.25%, 7.26%, 5.36%, and 4.1% of cases, respectively. Upon normalizing with confounding factors, the adjusted logistic regression model demonstrated that the moderate BSUA was independently linked to a lower risk of bone marrow suppression (OR=0.407,95% CI:0.178-0.931; p=0.033). Moreover, based on the Cox regression analysis, moderate BSUA was also independently correlated with a low mortality risk (HR=0.705, 95% CI:0.518-0.959; p=0.026).Conclusion:In males patients with stage IIIB or IV NSCLC, BSUA is intimately linked to chemotherapy-driven AE and ACM.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17046-17046
Author(s):  
A. Cassano ◽  
A. Pompucci ◽  
E. D’Argento ◽  
G. Schinzari ◽  
A. Di Chirico ◽  
...  

17046 Background: Lung cancer is the most common cause of cancer deaths and has the highest incidence for brain metastases of all malignancies. The prognosis of these patients (pts) remain poor with a median survival of 4–5 months. Whole brain radiation therapy (WBRT) in inoperable brain metastases prolongs survival to 3–5 months. In pts with 1 or ≤ 3 brain metastases neurosurgical resection improves median survival to 3.5–8 months. The aim of this study was to evaluate the long-term outcome of patients with brain metastases from NSCLC treated with multimodal strategy, including systemic chemotherapy, neurosurgery and radiotherapy. Methods: From 1997 to 2005, 56 pts were considered. Inclusion criteria were: single or multiple NSCLC brain metastases suitable of surgery; Karnofsky performance status ≥ 70%; controlled extracranial disease with Cisplatin-based chemotherapy; life expectancy > 4 months. Surgery was followed by 40 Gy WBRT. Statistical analysis was performed using the Kaplan-Meier method and Cox-regression analysis. Results: The median age was 58.4 years. The histological types were adenocarcinoma in 35 pts (62.5%), squamous cell carcinoma in 11 pts (19.7%) and large cell carcinoma in 10 pts (17.8%). The lesions were single in 39/56 pts (69.6%) and multiple in the other pts (30.4%). Radical surgery was performed in 37 pts (66%), while surgical citoreduction was possible in 19 pts (34%). The median follow-up period was 22.12 months (range 2–90 months). Overall survival (OS) of the whole group was 12.8 months; OS of pts radically resected was 16.5 months while OS of pts partially resected was 7.2 months. Based on Cox-regression analysis, age < 65 years and radical resection were independent predictors of survival (respectively p = 0.004–95% CI 1.46–7.6 and p = 0.04–95% CI 1.03–4.97), while the number of lesions was not relevant in terms of OS. Conclusions: Analysis of long-term outcome seems to confirm that the combined treatment of NSCLC brain metastases is a primary therapeutic option. In our series of 56 patients, radical surgery, not the number of metastases, was related with prolonged survival. Further randomized studies comparing surgery+WBRT vs gamma-knife-radiosurgery could define the best therapeutic option in the different subsets of pts. No significant financial relationships to disclose.


2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Qing Ma ◽  
Kai Geng ◽  
Ping Xiao ◽  
Lili Zeng

Background. Non-small-cell lung cancer (NSCLC) is a prevalent malignancy with high mortality and poor prognosis. The radiotherapy is one of the most common treatments of NSCLC, and the radiotherapy sensitivity of patients could affect the individual prognosis of NSCLC. However, the prognostic signatures related to radiotherapy response still remain limited. Here, we explored the radiosensitivity-associated genes and constructed the prognostically predictive model of NSCLC cases. Methods. The NSCLC samples with radiotherapy records were obtained from The Cancer Genome Atlas database, and the mRNA expression profiles of NSCLC patients from the GSE30219 and GSE31210 datasets were obtained from the Gene Expression Omnibus database. The Weighted Gene Coexpression Network Analysis (WGCNA), univariate, least absolute shrinkage and selection operator (LASSO), multivariate Cox regression analysis, and nomogram were conducted to identify and validate the radiotherapy sensitivity-related signature. Results. WGCNA revealed that 365 genes were significantly correlated with radiotherapy response. LASSO Cox regression analysis identified 8 genes, including FOLR3, SLC6A11, ALPP, IGFN1, KCNJ12, RPS4XP22, HIST1H2BH, and BLACAT1. The overall survival (OS) of the low-risk group was better than that of the high-risk group separated by the Risk Score based on these 8 genes for the NSCLC patients. Furthermore, the immune infiltration analysis showed that monocytes and activated memory CD4 T cells had different relative proportions in the low-risk group compared with the high-risk group. The Risk Score was correlated with immune checkpoints, including CTLA4, PDL1, LAG3, and TIGIT. Conclusion. We identified 365 genes potentially correlated with the radiotherapy response of NSCLC patients. The Risk Score model based on the identified 8 genes can predict the prognosis of NSCLC patients.


Sign in / Sign up

Export Citation Format

Share Document